Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to: 

• Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
• Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Activity Description

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

Faculty

Maria E. Arcila, MD
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC

Content Reviewer

Jason M. Chang, MD
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).

Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to: 

• Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
• Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Activity Description

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

Faculty

Maria E. Arcila, MD
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC

Content Reviewer

Jason M. Chang, MD
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).

Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

• Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
• Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
• Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
• Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies

Activity Description

This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.

Statement of Educational Need

Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Agenda

• Welcome & Introductions
• Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
• Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
• Future Directions and Emerging Data of BTK Inhibitor Therapy
• Considerations for Improving Patient Outcomes
• Conclusions

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Moderator
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

• Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
• Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
• Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
• Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies

Activity Description

This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.

Statement of Educational Need

Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Agenda

• Welcome & Introductions
• Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
• Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
• Future Directions and Emerging Data of BTK Inhibitor Therapy
• Considerations for Improving Patient Outcomes
• Conclusions

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Moderator
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

Statement of Commercial Support

Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com